Cited by 696Cancer survivorship and careCancer-related cognitive impairment studiesHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Esper, Peg, Mo, Fei, Chodak, Gerald, Sinner, Michael, Cella, David, Pienta, Kenneth J.·1997·Urology

DOI 10.1016/s0090-4295(97)00459-7

Open this paper in CoChat — free account

Abstract

Objectives As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer.Methods Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire.Results Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change.Conclusions Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer.

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(97)00459-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citation
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E., & Brook, R. H. (1995) · JAMA · doi:10.1001/jama.1995.03520260051032 · Cited by 1,020
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citation
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.129 · Cited by 281
The association of benign prostatic hyperplasia and cancer of the prostate
Bostwick, D. G., Cooner, W. H., Denis, L., Jones, G. W., Scardino, P. T., & Murphy, G. P. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1+ · Cited by 222
Early Detection of Prostate Cancer
Scardino, P. T. (1989) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)01800-0 · Cited by 210
Quality of Life and Functional Status Measures in Patients With Head and Neck Cancer
DʼAntonio, L. L., Zimmerman, G. J., Cella, D. F., & Long, S. A. (1996) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1996.01890170018005 · Cited by 197
Self-citation

Show all 22 references

Research works printed but not linked: 2

da Silva, 1993, Quality of life in patients with prostatic cancer. A feasibility study, Cancer, 71, 1138, 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7 · DOI
Esper, 1995, FACT-P: a new instrument for quality of life evaluation in prostate cancer (abstract), J Urol, 153

Sorted by citations

Items 101–200 of 696

Design of FRESH START: A Randomized Trial of Exercise and Diet among Cancer Survivors
Demark‐Wahnefried, W., Clipp, E. C., McBride, C. M., Lobach, D. F., Lipkus, I. M., Peterson, B. L., Snyder, D. C., Sloane, R. J., Arbanas, J. M., & Kraus, W. E. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000053704.28156.0f · Cited by 77
Study of dyadic communication in couples managing prostate cancer: a longitudinal perspective
Song, L., Northouse, L., Zhang, L., Braun, T., Cimprich, B., Ronis, D. L., & Mood, D. (2010) · Psycho-Oncology · doi:10.1002/pon.1861 · Cited by 77
Available evidence on HIFU for focal treatment of prostate cancer: a systematic review
Bakavičius, A., Marra, G., Macek, P., Robertson, C. N., Abreu, A. L., George, A. K., Malavaud, B. A., Coloby, P. J., Rischmann, P., Moschini, M., et al. (2022) · International braz j urol · doi:10.1590/s1677-5538.ibju.2021.0091 · Cited by 76
A Randomized Trial of Aerobic versus Resistance Exercise in Prostate Cancer Survivors
Mina, D. S., Alibhai, S. M. H., Matthew, A., Guglietti, C. L., Pirbaglou, M., Trachtenberg, J., & Ritvo, P. (2013) · Journal of Aging and Physical Activity · doi:10.1123/japa.21.4.455 · Cited by 76
“…training (RET; e.g., Galvao, Taaffe, Spry, Joseph, & Newton, 2010), home-based mixedmodality training (RET + aerobic exercise training [AET]; Culos-Reed, Robinson, Lau, O’Connor, & Keats, 2007; Culos-Reed et al., 2010), and facility-based mixedmodality training (Galvao et al., 2010).”
Effects of androgen deprivation on brain function in prostate cancer patients – a prospective observational cohort analysis
Chao, H. H., Uchio, E., Zhang, S., Hu, S., Bednarski, S. R., Luo, X., Rose, M. G., Concato, J., & Li, C. R. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-371 · Cited by 80
Determinants of Sexual Satisfaction in Men with Prostate Cancer
Nelson, C. J., Choi, J. M., Mulhall, J. P., & Roth, A. J. L. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00547.x · Cited by 75
OUTPATIENT RADICAL PROSTATECTOMY: IMPACT OF STANDARD PERINEAL APPROACH ON PATIENT OUTCOME
Ruiz-Deyá, G., Davis, R., Srivastav, S., Wise, A. M., & Thomas, R. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65988-5 · Cited by 75
Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT
Hamdy, F. C., Elliott, D., le Conte, S., Davies, L. C., Burns, R., Thomson, C., Gray, R. G., Wolstenholme, J. L., Donovan, J., Fitzpatrick, R. M., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22520 · Cited by 74
Functional status and the elderly cancer patient
Garman, K. S., & Cohen, H. J. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00062-8 · Cited by 74
“The prostate cancer patients had a mean age of 65 and the FACT showed internal validity, reliability and sensitivity to change [26].”
Background
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial
Khalaf, D. J., Sunderland, K., Eigl, B. J., Kollmannsberger, C., Ivanov, N., Finch, D. L., Oja, C. D., Vergidis, J., Zulfiqar, M., Gleave, M. E., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.12.015 · Cited by 75
Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy
Nishiyama, T., Kanazawa, S., Watanabe, R., Terunuma, M., & Takahashi, K. (2004) · International Journal of Urology · doi:10.1111/j.1442-2042.2004.00896.x · Cited by 72
Quality of life after treatment for prostate cancer
Penson, D. F., & Litwin, M. S. (2003) · Current Urology Reports · doi:10.1007/s11934-003-0068-1 · Cited by 71
“The FACT-P contains 38 items, each of which contains a statement that the patient may agree or disagree with across a five-point spectrum [ 17 ].”
Background
Differences in health-related quality of life of prostate cancer patients based on stage of cancer
Rosenfeld, B., Roth, A. J., Gandhi, S., & Penson, D. (2004) · Psycho-Oncology · doi:10.1002/pon.797 · Cited by 71
“…1983); the Functional Assessment of Cancer Therapy Scale (FACT), General and Prostate Modules developed by Cella and colleagues (Cella et al., 1993; Esper et al., 1997; Cella and Bonomi, 1996), a quality-of-life measure that includes subscales corresponding to physical well-being, social/family…”
Method
Pretreatment Quality of Life Predicts for Locoregional Control in Head and Neck Cancer Patients: A Radiation Therapy Oncology Group Analysis
Siddiqui, F., Pajak, T. F., Bruner, D. W., Konski, A. A., Coyne, J. C., Gwede, C. K., Garden, A. S., Spencer, S. A., Jones, C. U., & Movsas, B. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.024 · Cited by 72
Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy
Saini, A., Berruti, A., Cracco, C., Sguazzotti, E., Porpiglia, F., Russo, L. M., Bertaglia, V., Picci, R. L., Negro, M., Tosco, A., et al. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.02.005 · Cited by 72
A phase II trial of gefitinib in patients with non‐metastatic hormone‐refractory prostate cancer
Small, E. J., Fontana, J. A., Tannir, N. M., DiPaola, R. S., Wilding, G., Rubin, M. A., Iacona, R. B., & Kabbinavar, F. F. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07121.x · Cited by 72
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
Nussbaum, N. C., George, D. J., Abernethy, A. P., Dolan, C., Oestreicher, N., Flanders, S. C., & Dorff, T. B. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2015.42 · Cited by 71
Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer
Sullivan, P. W., Mulani, P. M., Fishman, M., & Sleep, D. J. (2007) · Quality of Life Research · doi:10.1007/s11136-006-9156-2 · Cited by 71
“Health-related quality of life was assessed using several validated scales: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), [9] the Functional Assessment of Cancer Therapy-Prostate (FACT-P) [ 10 ] and the EQ-5D index.”
Method
The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer
Evans, S., Millar, J. L., Wood, J. M., Davis, I. D., Bolton, D. M., Giles, G. G., Frydenberg, M., Frauman, A. G., Costello, A., & McNeil, J. J. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11530.x · Cited by 70
Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer
Sullivan, P. W., Nelson, J. B., Mulani, P. M., & Sleep, D. J. (2006) · Quality of Life Research · doi:10.1007/s11136-006-0003-2 · Cited by 70
“The Functional Assessment of Cancer Therapy – Prostate (FACT-P) was designed as a prostate cancer-specific version of the FACT [ 34 ].”
Method
Improving Couples’ Quality of Life Through a Web-Based Prostate Cancer Education Intervention
Song, L., Rini, C. K., Deal, A. M., Nielsen, M. E., Chang, H., Kinneer, P., Teal, R., Johnson, D. C., Dunn, M. W., Mark, B. A., et al. (2015) · Oncology nursing forum · doi:10.1188/15.onf.183-192 · Cited by 70
“Quality of life was measured using the 27-item Functional Assessment of Chronic Illness Therapy–General (FACT-G) scale (Cella et al., 1993), which measures general quality of life and quality of life in emotional, functional, physical, and social and family domains (Esper et al., 1997).”
Unmet supportive care needs in Hispanic/Latino cancer survivors: prevalence and associations with patient-provider communication, satisfaction with cancer care, and symptom burden
Moreno, P. I., Ramírez, A. G., Miguel‐Majors, S. L. S., Castillo, L., Fox, R. S., Gallion, K. J., Muñoz, E., Estabrook, R., Perez, A., Lad, T. E., et al. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4426-4 · Cited by 72
A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy
Liu, W., Zukotynski, K., Emmett, L., Chung, H. T.-K., Chung, P. W. M., Wolfson, R., Rachinsky, I., Kapoor, A., Metser, U., Loblaw, A., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.11.001 · Cited by 69
Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments
the EMPRO Group, Schmidt, S., Garín, O., Pardo, Y., Valderas, J. M., Alonso, J., Rebollo, P., Rajmil, L., Forero, C. G., & Ferrer, M. (2014) · Quality of Life Research · doi:10.1007/s11136-014-0678-8 · Cited by 69
Impact of providing audiotapes of primary treatment consultations to men with prostate cancer: a multi‐site, randomized, controlled trial
Hack, T. F., Pickles, T., Bultz, B. D., Ruether, J. D., & Degner, L. F. (2006) · Psycho-Oncology · doi:10.1002/pon.1094 · Cited by 69
Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire
King (2010) · Patient Related Outcome Measures · doi:10.2147/prom.s10621 · Cited by 68
Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial
Kaushik, D., Shah, P., Mukherjee, N. Z., Ji, N., Dursun, F., Kumar, A. P., Thompson, I. M., Mansour, A. M., Jha, R., Yang, X., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00470-w · Cited by 68
Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial
Fleshner, N. E., Gomella, L. G., Cookson, M. S., Finelli, A., Evans, A., Taneja, S. S., Lucia, M. S., Wolford, E. T., Somerville, M. C., & Rittmaster, R. S. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2007.05.006 · Cited by 68
“The Functional Assessment of Cancer Therapy, Prostate Module (FACT-P) [16] is a 39-item QOL questionnaire, which includes a 27-item core cancer QOL measure consisting of 4 subscales (ie, physical, social/family, emotional, and functional well-being) and a 12-item prostate cancer specific QOL module.”
Method
The EORTC quality of life questionnaire for patients with colorectal cancer: EORTC QLQ-CR29 validation study for Spanish patients
Arrarás, J. I., Suárez, J., de la Vega, F. A., Vera, R., Asín, G., Arrazubi, V., Rico, M., Teijeira, L., & Azparren, J. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0616-y · Cited by 68
RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy
Trinh, L., Arbour‐Nicitopoulos, K. P., Sabiston, C. M., Berry, S. R., Loblaw, A., Alibhai, S. M. H., Jones, J. M., & Faulkner, G. (2018) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-018-0686-0 · Cited by 67
Cryoablation as Primary Treatment for Localized Prostate Cancer Followed by Penile Rehabilitation
Ellis, D. S., Manny, T. B., & Rewcastle, J. C. (2007) · Urology · doi:10.1016/j.urology.2006.10.024 · Cited by 65
Endothelin-1-induced pain and hyperalgesia: A review of pathophysiology, clinical manifestations and future therapeutic options
Hans, G. H., Deseure, K. R., & Adriaensen, H. A. (2008) · Neuropeptides · doi:10.1016/j.npep.2007.12.001 · Cited by 65
Comparing Eccentric Resistance Exercise in Prostate Cancer Survivors On and Off Hormone Therapy: A Pilot Study
Hansen, P. A., Dechet, C., Porucznik, C. A., & LaStayo, P. C. (2009) · PM&R · doi:10.1016/j.pmrj.2009.09.016 · Cited by 63
A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT)
Massimo Valerio, A., Dickinson, L., Ali, A., Ramachandran, N., Donaldson, I. A., Freeman, A., Ahmed, H. U., & Emberton, M. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.07.006 · Cited by 63
Convergent Discriminitive, and Predictive Validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Assessment and Comparison with Analogous Scales From the EORTC QLQ-C30 and a Trial-Specific Module
Stockler, M. R., Osoba, D., Corey, P., Goodwin, P. J., & Tannock, I. F. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00025-6 · Cited by 63
Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials
Fred Saad, C., Ivanescu, C., Phung, D., Loriot, Y., Abhyankar, S. S., Beer, T. M., TOMBAL, B. F., & Holmström, S. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.62 · Cited by 63
Financial Hardship and Quality of Life among African American and White Cancer Survivors: The Role of Limiting Care Due to Cost
Hastert, T. A., Kyko, J. M., Reed, A. R., Harper, F. W. K., Beebe‐Dimmer, J., Baird, T. E., & Schwartz, A. G. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1336 · Cited by 63
Anxiety in the management of localised prostate cancer by active surveillance
Anderson, J. B., Burney, S., Brooker, J., Ricciardelli, L. A., Fletcher, J. M., Satasivam, P., & Frydenberg, M. (2014) · British Journal of Urology · doi:10.1111/bju.12765 · Cited by 62
Sexual functioning and quality of life after prostate cancer treatment: considering sexual desire
Dahn, J. R., Penedo, F. J., Gonzalez, J. S., Esquiabro, M., Antoni, M. H., Roos, B. A., & Schneiderman, N. (2004) · Urology · doi:10.1016/j.urology.2003.09.048 · Cited by 62
Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial
Bjerre, E. D., Brasso, K., Jørgensen, A. B., Petersen, T. H., Eriksen, A., Tolver, A., Christensen, J. F., Poulsen, M. H., Madsen, S. S., Østergren, P. B., et al. (2018) · Sports Medicine · doi:10.1007/s40279-018-1031-0 · Cited by 61
A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer
Lee, W. R., McQuellon, R. P., Harris‐Henderson, K., Case, L. D., & McCullough, D. L. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00355-7 · Cited by 61
Factors associated with adherence to physical activity guidelines in patients with prostate cancer
Chipperfield, K., Fletcher, J. M., Millar, J. L., Brooker, J., Smith, R., Frydenberg, M., Oh, T., & Burney, S. (2013) · Psycho-Oncology · doi:10.1002/pon.3310 · Cited by 60
“69 [38,39].”
Health‐related quality of life in men with localized prostate cancer
Namiki, S., & Arai, Y. (2009) · International Journal of Urology · doi:10.1111/j.1442-2042.2009.02437.x · Cited by 60
Hypofractionation for clinically localized prostate cancer
Hickey, B. E., James, M. L., Daly, T., Soh, F.-Y., & Jeffery, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011462.pub2 · Cited by 63
Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05
Feigenberg, S. J., Lee, W. R., DeSilvio, M., Winter, K., Pisansky, T. M., Bruner, D. W., Lawton, C. A., Morton, G., Baikadi, M., & Sandler, H. M. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.12.061 · Cited by 60
A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy
Alibhai, S. M. H., Mina, D. S., Ritvo, P., TOMLINSON, G. A., Sabiston, C. M., Krahn, M. D., Durbano, S., Matthew, A., Warde, P. R., O’Neill, M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-018-5189-5 · Cited by 60
Quality of life following high‐intensity focused ultrasound for the treatment of localized prostate cancer: A prospective study
Shoji, S., Nakano, M., Nagata, Y., Usui, Y., Terachi, T., & Uchida, Τ. (2010) · International Journal of Urology · doi:10.1111/j.1442-2042.2010.02568.x · Cited by 58
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients
Noguchi, M., Itoh, K., Yao, A., Mine, T., Yamada, A., Obata, Y., Furuta, M., Harada, M., Suekane, S., & Matsuoka, K. (2004) · The Prostate · doi:10.1002/pros.20157 · Cited by 58
American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy
Nag, S. K., Ellis, R. J., Merrick, G. S., Bahnson, R., Wallner, K. E., & Stock, R. G. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02937-1 · Cited by 56
Exercise training to increase tumour natural killer‐cell infiltration in men with localised prostate cancer: a randomised controlled trial
Djurhuus, S. S., Simonsen, C., Toft, B. G., Thomsen, S. N., Wielsøe, S., Røder, M. A., Hasselager, T., Østergren, P. B., Jakobsen, H. L., Pedersen, B. K., et al. (2022) · British Journal of Urology · doi:10.1111/bju.15842 · Cited by 57
A pilot study examining the effects of low-volume high-intensity interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors
Toohey, K. L., Pumpa, K. L., Arnolda, L., Cooke, J., Yip, D., Craft, P., & Semple, S. (2016) · PeerJ · doi:10.7717/peerj.2613 · Cited by 58
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study
Stenzl, A., Dunshee, C. J., Giorgi, U. D., Alekseev, B. Y., Iguchi, T., Szmulewitz, R. Z., Flaig, T. W., TOMBAL, B. F., Morlock, R., Ivanescu, C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.019 · Cited by 57
Nerve-sparing robot-assisted radical prostatectomy: Current perspectives
Kumar, A., Patel, V., Panaiyadiyan, S., Bhat, K. R. S., Moschovas, M. C., & Nayak, B. (2020) · Asian journal of urology · doi:10.1016/j.ajur.2020.05.012 · Cited by 57
Symptom burden among patients with Renal Cell Carcinoma (RCC): content for a symptom index
Harding, G., Cella, D. F., Robinson, D., Mahadevia, P. J., Clark, J., & Revicki, D. A. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-34 · Cited by 57
“of interest (Figure 2). Questions were included from the Functional Assessment of Cancer Therapy-General (FACT-General) [46] as well as items from the prostate cancer (FACT-P) [ 47 ], lung cancer (FACT-L) [48], fatigue (FACT-F) [49,50], hepatobiliary cancer (FACT-HEP) [51], and biological response modifier (FACT-BRM)…”
MethodSelf-citation
EARLY QUALITY OF LIFE ASSESSMENT IN MEN TREATED WITH PERMANENT SOURCE INTERSTITIAL BRACHYTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER
Lee, W. R., McQuellon, R. P., Case, L. D., deGuzman, A. F., & McCullough, D. L. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68570-9 · Cited by 57
Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy
Chipperfield, K., Fletcher, J., Millar, J., Brooker, J., Smith, R., Frydenberg, M., & Burney, S. (2013) · Psycho-Oncology · doi:10.1002/pon.3269 · Cited by 56
“Developed as a disease-specific adjunct to the FACT measurement system, the 12-item prostate cancer subscale (PCS) measures symptoms specific to PCa [51] and has adequate psychometric properties [51,52].”
Method
Clinical and epidemiological observations on individual radiation sensitivity and susceptibility
Seibold, P., Auvinen, A., Averbeck, D., Bourguignon, M., Hartikainen, J. M., Hoeschen, C., Laurent, O., Noël, G., Sabatier, L., Salomaa, S., et al. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1665209 · Cited by 56
“For prostate cancer, for example, these include EPIC (Expanded prostate cancer index composite, Wei et al. 2000), FACT-P (Functional Assessment of Cancer Therapy – Prostate, Esper et al. 1997) or EORTC QLQ PR25 (van Andel et al. 2008) questionnaires.”
Method
Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G
King, M. T., Stockler, M. R., Cella, D. F., Osoba, D., Eton, D. T., Thompson, J., & Eisenstein, A. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.05.001 · Cited by 58
Self-citation
Effects of Androgen Deprivation on Cerebral Morphometry in Prostate Cancer Patients – An Exploratory Study
Chao, H. H., Hu, S., Ide, J. S., Uchio, E., Zhang, S., Rose, M. G., Concato, J., & Li, C.-S. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072032 · Cited by 56
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
Eymard, J.-C., Priou, F., Zannetti, A., Ravaud, A., Lepille, D., Kerbrat, P., Gomez, P. S., Paule, B., Genet, D., Herait, P., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm083 · Cited by 56
“QoL was assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire [22], Annals of Oncology original article”
Method
Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale.
Cormier, J. N., Davidson, L., Xing, Y., Webster, K., & Cella, D. F. (2005) · PubMed · Cited by 56
Self-citation
Clinical, Demographic and Psychosocial Correlates of Complementary and Alternative Medicine Use by Men Diagnosed With Localized Prostate Cancer
Diefenbach, M. A., Hamrick, N., Uzzo, R. G., Pollack, A. S., Horwitz, E. M., Greenberg, R. E., & Engstrom, P. F. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000070963.12496.cc · Cited by 56
Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial
Bjerre, E. D., Petersen, T. H., Jørgensen, A. B., Johansen, C., Krustrup, P., Langdahl, B. L., Poulsen, M. H., Madsen, S. S., Østergren, P. B., Borre, M., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002936 · Cited by 56
Randomized Trial to Assess the Impact of Venlafaxine and Soy Protein on Hot Flashes and Quality of Life in Men With Prostate Cancer
Vitolins, M. Z., Griffin, L. P., Tomlinson, W. V., Vuky, J., Adams, P. T., Moose, D., Frizzell, B. A., Lesser, G. J., Naughton, M., Radford, J. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1432 · Cited by 55
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study
Kornblith, A. B., Herndon, J. E., Zuckerman, E., Godley, P. A., Savarese, D. M. F., Vogelzang, N., & Holland, J. C. (2001) · Annals of Oncology · doi:10.1023/a:1011102619058 · Cited by 56
Perceptions of masculinity and body image in men with prostate cancer: the role of exercise
Langelier, D. M., Cormie, P., Bridel, W., Grant, C. J., Albinati, N. K., Shank, J., Daun, J. T., Fung, T. S., Davey, C., & Culos-Reed, S. N. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4178-1 · Cited by 54
Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy
Monga, U., Kerrigan, A. J., Thornby, J. A., Monga, T. N., & Zimmermann, K. P. (2005) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2004.06.0071 · Cited by 54
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
Ahlgren, G., Flodgren, P., Tammela, T. L. J., Kellokumpu‐Lehtinen, P., Borre, M., Angelsen, A., Iversen, J. R., Sverrisdóttir, Á., Jónsson, E., & Sengeløv, L. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.012 · Cited by 54
The "Palliative Care Quality of Life Instrument (PQLI)" in terminal cancer patients.
Mystakidou, K., Tsilika, E., Kouloulias, V., Parpa, E., Katsouda, E., Kouvaris, J., & Vlahos, L. J. (2004) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-2-8 · Cited by 54
“It was found to be concise, quantitative and easily used; it has been designed primarily for use by the patients themselves; it was based on the existing literature [7, 9-11 ] and the items that the patients consider as most important to what they perceive as "quality of life", the latter was elicited by means of qual…”
Method
THE JAPANESE TRANSLATION AND CULTURAL ADAPTATION OF EXPANDED PROSTATE CANCER INDEX COMPOSITE (EPIC)
Takegami, M., Suzukamo, Y., Kamoto, T., Namiki, S., Arai, Y., Ogawa, O., Fukuhara, S., Kakehi, Y., & Sanda, M. G. (2005) · The Japanese Journal of Urology · doi:10.5980/jpnjurol1989.96.657 · Cited by 52
Reclaiming Wellness-Living With Bodily Problems, As Narrated by Men With Advanced Prostate Cancer
Lindqvist, O., Widmark, A., & Rasmussen, B. H. (2006) · Cancer Nursing · doi:10.1097/00002820-200607000-00012 · Cited by 52
Distress, anxiety, depression, and emotional well-being in African-American men with prostate cancer
Nelson, C. J., Balk, E. M., & Roth, A. J. (2010) · Psycho-Oncology · doi:10.1002/pon.1659 · Cited by 49
The Validity and Utility of the M. D. Anderson Symptom Inventory in Patients With Breast Cancer: Evidence From the Symptom Outcomes and Practice Patterns Data From the Eastern Cooperative Oncology Group
Mendoza, T. R., Zhao, F., Cleeland, C. S., Wagner, L. I., Patrick‐Miller, L. J., & Fisch, M. J. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.02.014 · Cited by 50
Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial
Brundage, M., Sydes, M. R., Parulekar, W. R., Warde, P. R., Cowan, R. A., Bezjak, A., Kirkbride, P., Parliament, M. B., Moynihan, C., Bahary, J.-P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.8724 · Cited by 50
Patient-reported outcomes in cancer survivorship
Gordon, B.-B. E., & Chen, R. C. (2017) · Acta Oncologica · doi:10.1080/0284186x.2016.1268265 · Cited by 50
Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer
Ritvo, P., Irvine, J., Naglie, G., TOMLINSON, G. A., Bezjak, A., Matthew, A., Trachtenberg, J., & Krahn, M. D. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.08.019 · Cited by 50
Patient and Partner Quality of Life and Psychosocial Adjustment Following Radical Prostatectomy
Thornton, A. A., Perez, M. A., & Meyerowitz, B. E. (2004) · Journal of Clinical Psychology in Medical Settings · doi:10.1023/b:jocs.0000016266.06253.95 · Cited by 50
“…health-related quality of life, we also measured patient diseasespecific quality of life with the Functional Assessment of Cancer Treatment-Prostate version (FACT-P; Cella, 1994), a standardized instrument with demonstrated validity and reliability (α for all scales > .64; Esper et al., 1997).”
MethodResultInfluential
Does trunk muscle training with an oscillating rod improve urinary incontinence after radical prostatectomy? A prospective randomized controlled trial
Heydenreich, M., Puta, C., Gabriel, H. H. W., Dietze, A., Wright, P. R., & Zermann, D. (2019) · Clinical Rehabilitation · doi:10.1177/0269215519893096 · Cited by 51
COMPARISON OF PATIENT AND SPOUSE ASSESSMENTS OF HEALTH RELATED QUALITY OF LIFE IN MEN WITH METASTATIC PROSTATE CANCER
Sneeuw, K. C. A., Albertsen, P. C., & Aaronson, N. K. (2001) · The Journal of Urology · doi:10.1097/00005392-200102000-00029 · Cited by 49
Investigating the role of psychological flexibility, masculine self‐esteem and stoicism as predictors of psychological distress and quality of life in men living with prostate cancer
McAteer, G., & Gillanders, D. (2019) · European Journal of Cancer Care · doi:10.1111/ecc.13097 · Cited by 47
“This subscale of the FACT-P has demonstrated acceptable validity with α=.69 (Esper et al., 1997).”
BackgroundMethod
Patient-reported outcome measures in urology
Narang, G., Pannell, S. C., Laviana, A. A., Huen, K. H. Y., Izard, J., Smith, A. B., & Bergman, J. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000412 · Cited by 47
Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial
Mina, D. S., Matthew, A., Hilton, W. J., Au, D., Awasthi, R., Alibhai, S. M. H., Clarke, H. A., Ritvo, P., Trachtenberg, J., Fleshner, N. E., et al. (2014) · BMC Surgery · doi:10.1186/1471-2482-14-89 · Cited by 48
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hansen, A. R., Tannock, I. F., Templeton, A. J., Chen, E. X., Evans, A., Knox, J. J., Prawira, A., Sridhar, S. S., Tan, S., Vera-Badillo, F., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0621 · Cited by 46
Does “normal” aging imply urinary, bowel, and erectile dysfunction? A general population survey
Korfage, I. J., Roobol, M., de Koning, H. J., Kirkels, W. J., Schröder, F. H., & Essink-Bot, M.-L. (2008) · Urology · doi:10.1016/j.urology.2008.01.058 · Cited by 45
Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents
Bahl, A. K., Masson, S., Birtle, A. J., Chowdhury, S., & Bono, J. S. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.008 · Cited by 45
“The QoL response rate, assessed by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire [30], was increased vs.”
Method
Randomized Controlled Trial of a Behavior Change Intervention to Increase Physical Activity and Quality of Life in Prostate Cancer Survivors
McGowan, E. L., North, S. A., & Courneya, K. S. (2013) · Annals of Behavioral Medicine · doi:10.1007/s12160-013-9519-1 · Cited by 45
?-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma
Cook, N. R., Stampfer, M. J., Ma, J., Manson, J. E., Sacks, F. M., Buring, J. E., & Hennekens, C. H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991101)86:9 · Cited by 121
Reliability and validity of the Functional Assessment of Cancer Therapy General (FACT-G) in French cancer patients
Costet, N., Lapierre, V., Benhamou, E., & Galès, C. L. (2005) · Quality of Life Research · doi:10.1007/s11136-004-5531-z · Cited by 44
Evaluation of an evidence-based education package for men with prostate cancer on hormonal manipulation therapy
Templeton, H. R. M., & COATES, V. E. (2003) · Patient Education and Counseling · doi:10.1016/j.pec.2003.07.005 · Cited by 43
“QOL was assessed using the Functional Assessment of Cancer Therapy-Prostate cancer version (FACT-P) [18].”
Method
Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study
Wu, L. M., Amidi, A., Tanenbaum, M. L., Winkel, G. H., Gordon, W. A., Hall, S. J., Bovbjerg, K., & Diefenbach, M. A. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-4026-8 · Cited by 44
“The 39-item Functional Assessment of Cancer Therapy–Prostate [30] measures quality of life using a 5-point Likert scale.”
Method
Development of the Functional Assessment of Cancer Therapy–Immune Checkpoint Modulator (FACT‐ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs
Hansen, A. R., Ala‐Leppilampi, K., McKillop, C., Siu, L. L., Bedard, P. L., Razak, A. R. A., Spreafico, A., Sridhar, S. S., Leighl, N. B., Butler, M. O., et al. (2020) · Cancer · doi:10.1002/cncr.32692 · Cited by 41
“Audio recordings of physician interviews were transcribed and subjected to descriptive thematic analysis.(14,15)”
MethodSelf-citation
Measuring symptoms in localized prostate cancer: a systematic review of assessment instruments
Rnic, K., Linden, W., Tudor, I., Pullmer, R., & Vodermaier, A. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.1 · Cited by 42
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
Staffurth, J. N., Haviland, J., Wilkins, A. C., Syndikus, I., Khoo, V. S., Bloomfield, D. J., Parker, C. C., Logue, J. P., Scrase, C. D., Birtle, A. J., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.07.005 · Cited by 42
Body image predicts quality of life in men with prostate cancer
Taylor‐Ford, M., Meyerowitz, B. E., D'Orazio, L. M., Christie, K. M., Gross, M. E., & Agus, D. B. (2013) · Psycho-Oncology · doi:10.1002/pon.3063 · Cited by 41
“Quality of life was assessed at T1 and T3 with the Functional Assessment of Cancer Treatment—General Scale (FACT-G) [31], a 27-item scale that measures physical, social, emotional, and functional health-related QOL.”
MethodInfluential
Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Shirley, M., & McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-014-0198-4 · Cited by 41
The physical burden of prostate cancer
Penson, D. F., & Litwin, M. S. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(02)00187-8 · Cited by 41
“[10] Esper P, Mo F, Chodak G, et al.”
BackgroundMethod
The families evaluation on management, care and disclosure for terminal stage cancer patients
Mystakidou, K., Parpa, E., Tsilika, E., Kalaidopoulou, O., & Vlahos, L. J. (2002) · BMC Palliative Care · doi:10.1186/1472-684x-1-3 · Cited by 40
“The questionnaire was designed to be self-assessment and was formulated after a thorough review of the relevant literature, incorporating previously validated questions from other scales and measures appropriate for use in palliative care settings for the assessment of relatives' patient management perceptions and cho…”
Systemic treatment for prostate cancer
DOWLING, A. J., & Tannock, I. F. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90062-7 · Cited by 40
Measuring Health-Related Quality of Life Consequences From Primary Treatment for Early-Stage Prostate Cancer
Dandapani, S. V., & Sanda, M. G. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2007.10.001 · Cited by 39
“[3,4] Early studies in the development of these HRQOL instruments sought to identify various HRQOL domains impacted by common primary prostate cancer treatments, and to refine and adapt the questionnaires to be sensitive to a broad array of clinically significant side effects as measured from the patient's perspective.”
Background
Community-Based Recreational Football: A Novel Approach to Promote Physical Activity and Quality of Life in Prostate Cancer Survivors
Bruun, D. M., Bjerre, E. D., Krustrup, P., Brasso, K., Johansen, C., Rørth, M. R., & Midtgaard, J. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110605567 · Cited by 39

Authors: Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J.
Affiliations: Rush University Medical Center (US)
Corresponding author: Esper, Peg
ORCID: Cella, David
Pienta, Kenneth J.
Venue: Urology
Publisher: Elsevier BV
Published: 1997-12
Volume: 50
Issue: 6
Pages: 920-928
ISSN: 0090-4295 (ISSN-L)
DOI: 10.1016/s0090-4295(97)00459-7
OpenAlex: W2004909463
Cited by: 696
References: 22
Citations by year: 2026: 18 · 2025: 22 · 2024: 34 · 2023: 25 · 2022: 45 · 2021: 34 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 29 · 2016: 33 · 2015: 30 · 2014: 28 · 2013: 31 · 2012: 27
FWCI: 4.00
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Urology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords: prostate cancer, quality of life, Functional Assessment of Cancer Therapy, questionnaire development, concurrent validity, internal consistency, sensitivity to change, prostate-specific antigen, performance status, disease stage
MeSH terms: Aged, Aged, 80 and over, Chicago, Humans, Male, Michigan, Middle Aged, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks